Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines

1 May 2005

Abstract excerpt

Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. It has proved beneficial in treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates activity against malignant cells expressing c-kit and platelet-derived growth factor receptor (PDGF-R). The activity of IM in the blastic crisis of CML...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Telomeres, Telomerase, and Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15870711
DOI: 10.1038/sj.bjc.6602592

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell linesPMID 15870711Read ↗

Inhibition of TERT suppressed proliferation and induced apoptosis in chronic myeloid leukemia cellsSemantic proximity Read ↗

Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.Semantic proximity Read ↗

Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.Semantic proximity Read ↗

Regulation and Targeting of Eg5, a Mitotic Motor Protein in Blast Crisis CML: Overcoming Imatinib ResistanceSemantic proximity Read ↗

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer CellsSemantic proximity Read ↗

Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532Semantic proximity Read ↗

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genesSemantic proximity Read ↗

Imatinib effect on growth and signal transduction in polycythemia vera.Semantic proximity Read ↗

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Semantic proximity Read ↗

Inhibitory effect of imatinib on normal progenitor cells in vitroSemantic proximity Read ↗

[Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].Semantic proximity Read ↗

Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.